The 1989 Surgeon General’s report, which assessed numerous case-control and cohort studies, reported that<unk>  increased cardiovascular disease mortality by 50%. Cigarette<unk> , likely due to the hemodynamic consequences of sympathetic neural stimulation and systemic catecholamine release, plays an important role in the pathogenesis of coronary artery disease. Cigarette<unk>  also forms a major risk factor for acute cardiovascular events as it relates to an associated increase in blood coagulability. Hence, cigarette<unk>  is an important reversible risk factor in the pathogenesis of CAD and<unk>  of which improves prognosis and is associated with a substantial decrease in the risk of mortality. In patients with stable angina pectoris, nicotine replacement therapy has shown to be potentially beneficial despite the associated cardiovascular risks of nicotine, such as increase in heart rate with a small rise in blood pressure. Nicotine replacement therapy may be initiated as early as 2–3 days after acute myocardial infarction or cardiac arrhythmias.  Additionally, nicotine patches have been used successfully in high-risk patients without any adverse effects such as aggravation of MI or arrhythmia.
Chronic stable angina treatment smoking cessation
Chronic stable angina treatment weight management
Chronic stable angina treatment physical activity
Chronic stable angina treatment lipid management
Chronic stable angina treatment diabetes control
Chronic stable angina treatment blood pressure control
Chronic stable angina medical therapy
Chronic stable angina revascularization percutaneous coronary intervention